EVP, Commercial of Seagen Inc (30-Year Financial, Insider Trades) Charles R Romp (insider trades) sold 14,079 shares of SGEN on 11/04/2020 at an average price of $180.37 a share. The total sale was $2.5 million.
Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada. Seagen Inc has a market cap of $31.08 billion; its shares were traded at around $173.63 with a P/E ratio of 68.36 and P/S ratio of 16.56. GuruFocus has detected 1 severe warning sign with Seagen Inc. .
Directors and Officers Recent Trades:
- Director David W Gryska sold 4,500 shares of SGEN stock on 11/05/2020 at the average price of $180.6. The price of the stock has decreased by 3.86% since.
- Chief Medical Officer Roger D Dansey sold 7,661 shares of SGEN stock on 11/04/2020 at the average price of $177. The price of the stock has decreased by 1.9% since.
- EVP, Commercial Charles R Romp sold 14,079 shares of SGEN stock on 11/04/2020 at the average price of $180.37. The price of the stock has decreased by 3.74% since.
- EVP, Commercial Charles R Romp sold 19,062 shares of SGEN stock on 11/03/2020 at the average price of $168.45. The price of the stock has increased by 3.08% since.
- Director Marc E Lippman sold 142,090 shares of SGEN stock on 11/03/2020 at the average price of $168.61. The price of the stock has increased by 2.98% since.
For the complete insider trading history of SGEN, click here
.
